Invasion Assay. Local invasion of M231 cells was investigated using 24-well cell culture Boyden chambers (BD Biosciences). Cells (1 x 10 5 per well) were plated atop Matrigelcoated membranes containing 8 µm pores. Cells that penetrated the membrane were stained using 0.5% crystal violet and counted using the ImageJ program. All experiments were performed at least twice, and three separate replicates of each culture were analyzed under each experimental condition.
Colony Formation Assay. Cells were seeded on plastic plates in growth medium. Colonies were stained using 0.5% crystal violet 2 wk post-seeding and counted using the ImageJ program. All experiments were performed at least twice, and three separate replicates of each culture were analyzed.
Antibodies, Immunoblotting, and Immunoprecipitation (IP).
The following antibodies were used: E-cadherin (610404, BD Transduction Lab), N-cadherin (610920, BD Transduction Lab), b-Catenin (610153, BD Transduction Lab), V5 (A190-120A, Bethyl), BRCA1 (A300-000A, Bethyl), HA (901501, BioLegend), Vimentin (IF01, Calbiochem), AKT (#9272, Cell Signaling), phospho-AKT (#9275, Cell Signaling), phospho-b-Catenin (#9561, Cell Signaling), GSK-3b (#9315, Cell Signaling), phospho-GSK-3b (#5558, Cell Signaling), HDAC1 (#5356, Cell Signaling), PTEN (#9188, Cell Signaling), Slug (#9585, Cell Signaling), Snail (#3879, Cell Signaling), ARNT (NB100-110, Novus), HIF-1a (NB100-134, Novus), Myc (sc-40, Santa Cruz), Actin (A5441, Sigma), and Vinculin (V4505, Sigma). Western blot and IP were carried out as described previously (5) with specific antibodies.
Anti-human IRIS antibody was raised in rabbits immunized with the intron-11 peptide (N-GIGTRFLCLPQSIYRSELNVYAFGEHILQISKYS-C) fused to glutathione Stransferase. IRIS-specific polyclonal rabbit antibody was affinity-purified using a synthetic peptide of the same sequence as the immunogen.
Plasmids and Mutagenesis. Myc-FL IRIS and Myc-Tr IRIS (lacking all sequences encoded by the BRCA1 intron 11) were generated by PCR, using full-length IRIS cDNA as the template, and were cloned into the pLX304 (Addgene) (6) vector through Gateway cloning (Life Technologies).
The WT HIF-1a cDNA was also cloned into the pLX304 vector. The STA (Ser551Ala, Thr555Ala and Ser589Ala) HIF-1a construct was generated with a QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent) according to the manufacturer's protocol. All constructs were confirmed as accurate by sequencing analyses.
Protein Half-life Experiments. Protein half-life was estimated in cycloheximide-chase experiments. Specifically, cultures of M231 cells transduced with various hairpins and/or protein expression vectors were treated with 50 µg/ml cycloheximide (Calbiochem) and whole cell extracts of the indicated culture were collected at indicated time points. To mimic a hypoxic condition, cells were pretreated with 1 mM DMOG (Sigma Aldrich) for 12 hr. Band intensities in Western blots were quantified using the ImageJ program.
Xenograft Studies and Histological Analysis. For subcutaneous or primary tumor growth, M231 cells carrying shIRIS or control shRNA were mixed with 40% Matrigel (BD Biosciences) in PBS, and 2 x 10 6 cells were inoculated subcutaneously or into the mammary fat pads of 6-wk-old, intact female nude mice (Charles River Laboratories). Subsequent tumor size was measured with a caliper, and tumor volume was calculated using the equation: Volume = Length x Width 2 /2. All mice in mammary fat pad injection experiments were euthanized, and their tissues were fixed 7 wk post-injection. Fixed tissues were used for histological analysis in search of evidence of metastasis.
For metastasis assays, intact female SCID-beige mice (6-wk-old, Charles River Laboratories) were inoculated intravenously or by intracardiac injection of M231 cells (2 x 10 6 per mouse) stably transduced with various hairpins and/or protein expression vectors. All mice were euthanized and fixed 3 wk post-transplantation for further histopathological analysis to assay for metastasis. Mice carrying BC3-p53KD cells (1 x  10 6 per animal) were euthanized and fixed 7 wk post-transplantation. Histopathological analysis was performed blindly by experts in the DF/HCC Rodent Histopathology Core facility.
Metastatic burden was analyzed and quantified as described previously (7). This method involves the quantitation of metastatic tumor deposits present in a standard number of sections of each organ and tissue destined to be evaluated. Typically, metastases were sought in lung, heart, brain, eye, bone, bone marrow, liver, kidney, adrenal glands, pancreas, spleen, muscle, lymph nodes, mesentery, mediastinum, fat, intestine, stomach, ovary, uterus, and connective tissues.
Analysis of RNA-Seq Data. The Kallisto estimates of p220 and IRIS abundance were extracted from the dataset cgc-05-0002 on the Institute for Systems Biology Google Cloud (https://bigquery.cloud.google.com). Access to controlled data (FASTQ) was approved through the Database of Genotypes and Phenotypes (dbGaP), and analyses were performed in accordance with Data Use Certification and the local IRB protocol 16-368. Expression levels were defined in a log2+1 format. An empirical Bayes batch effect correction algorithm, ComBat (8), was applied using the sva package in Bioconductor to retain the disease-related information and to remove the platform effects. See Dataset S1 for adjusted expression data.
A general cutoff of 0.1 TPM was used for filtering of low transcript counts (9) . Cancer types having fewer than 3 cases with IRIS transcript counts of >0.1 TPM were considered as baseline level IRIS-expressing groups. Cancer types including at least 3 cases with >0.1 TPM IRIS levels were considered elevated IRIS-expressing cancer types. The exactTest in Bioconductor package edgeR (10) was used to compare IRIS transcript levels in each elevated IRIS-expressing type to those in all baseline level IRIS-expressing types combined. P values were adjusted for multiple testing with Benjamini & Hochberg FDR correction. The code to reproduce analysis is available on https://github.com/aedin.
Due to low levels of IRIS abundance estimated by Kallisto in all TCGA cases, a direct counting approach was used to examine the relationship between IRIS and PTEN expression in the TCGA breast cancer dataset. Reads that map to the intron 11 sequence of the IRIS transcript in public alignments (BAM files downloaded from the UCSC Cancer Genomics Hub server) were counted using featureCounts in the Rsubread R package (11) . Counts were normalized over the total number of reads using the median ratio method (Eqn 5) (12) and the DESeq2 package in Bioconductor (primary functions, estimateSizeFactors, fpkm). The library size (total number of reads) was estimated from the Level-3 exon data. The PTEN mutation and mRNA expression data were extracted from the processed Level-3 TCGA data. All cases with no read in any of BRCA1 exons were excluded from the analysis. Cases with homozygous BRCA1 deletion or early nonsense mutations were removed from the analysis. Any cases subjected to a reporting bias were also removed from the analysis. See Dataset S4 for patient ID numbers and expression data. Dataset S4. ID numbers and expression data associated with tumors in the TCGA breast cancer dataset.
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